Qi Y, Wang X, Qin L
Brief Bioinform. 2025; 26(2).
PMID: 40072846
PMC: 11899567.
DOI: 10.1093/bib/bbaf097.
Zareba P, Drabczyk A, Wnorowski A, Maj M, Rurka P, Malarz K
ACS Omega. 2025; 10(7):6446-6469.
PMID: 40028084
PMC: 11866022.
DOI: 10.1021/acsomega.4c06456.
Kazerooni A, Akbari H, Hu X, Bommineni V, Grigoriadis D, Toorens E
Commun Med (Lond). 2025; 5(1):55.
PMID: 40025245
PMC: 11873127.
DOI: 10.1038/s43856-025-00767-0.
Han H, Du A, Li J, Han H, Feng P, Zhu Y
Oncol Rep. 2025; 53(4).
PMID: 40017136
PMC: 11894601.
DOI: 10.3892/or.2025.8881.
Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A
Mol Cancer. 2025; 24(1):58.
PMID: 40011944
PMC: 11863469.
DOI: 10.1186/s12943-025-02267-0.
Heterogeneous Clustering of Multiomics Data for Breast Cancer Subgroup Classification and Detection.
Pateras J, Lodi M, Rana P, Ghosh P
Int J Mol Sci. 2025; 26(4).
PMID: 40004168
PMC: 11855380.
DOI: 10.3390/ijms26041707.
Advancing Glioblastoma Research with Innovative Brain Organoid-Based Models.
Correia C, Calado S, Matos A, Esteves F, De Sousa-Coelho A, Campinho M
Cells. 2025; 14(4).
PMID: 39996764
PMC: 11854129.
DOI: 10.3390/cells14040292.
Research trends in glioma chemoradiotherapy resistance: a bibliometric analysis (2003-2023).
Yu S, Wu J, Jing Y, Lin P, Lang L, Xiong Y
Front Oncol. 2025; 15:1539937.
PMID: 39990688
PMC: 11842341.
DOI: 10.3389/fonc.2025.1539937.
Harnessing ferroptosis for precision oncology: challenges and prospects.
Fernandez-Acosta R, Vintea I, Koeken I, Hassannia B, Vanden Berghe T
BMC Biol. 2025; 23(1):57.
PMID: 39988655
PMC: 11849278.
DOI: 10.1186/s12915-025-02154-6.
In Vitro Functional Validation of an Anti-FREM2 Nanobody for Glioblastoma Cell Targeting.
Krapez G, Samec N, Zottel A, Katrasnik M, Kump A, Sribar J
Antibodies (Basel). 2025; 14(1).
PMID: 39982223
PMC: 11843905.
DOI: 10.3390/antib14010008.
Analysis of transcription profiles for the identification of master regulators as the key players in glioblastoma.
Ivanov S, Lagunin A, Tarasova O
Comput Struct Biotechnol J. 2025; 23:3559-3574.
PMID: 39963421
PMC: 11832006.
DOI: 10.1016/j.csbj.2024.09.022.
Virtual Biopsy for the Prediction of MGMT Promoter Methylation in Gliomas: A Comprehensive Review of Radiomics and Deep Learning Approaches Applied to MRI.
Leone A, Di Napoli V, Fochi N, Di Perna G, Spetzger U, Filimonova E
Diagnostics (Basel). 2025; 15(3).
PMID: 39941181
PMC: 11816478.
DOI: 10.3390/diagnostics15030251.
An integrated perspective on single-cell and spatial transcriptomic signatures in high-grade gliomas.
Lemoine C, Da Veiga M, Rogister B, Piette C, Neirinckx V
NPJ Precis Oncol. 2025; 9(1):44.
PMID: 39934275
PMC: 11814291.
DOI: 10.1038/s41698-025-00830-y.
Low & Anaplastic Grade Glioma Umbrella Study of MOlecular Guided TherapieS (LUMOS-2): study protocol for a phase 2, prospective, multicentre, open-label, multiarm, biomarker-directed, signal-seeking, umbrella, clinical trial for recurrent IDH....
McParland K, Koh E, Kong B, Sim H, Thavaneswaran S, Yip S
BMJ Open. 2025; 15(2):e087922.
PMID: 39929517
PMC: 11815451.
DOI: 10.1136/bmjopen-2024-087922.
Actionable alterations in glioblastoma: Insights from the implementation of genomic profiling as the standard of care from 2016 to 2023.
Fougner V, Urup T, Poulsen H, Grunnet K, Westmose C, Melchior L
Neurooncol Pract. 2025; 12(1):34-44.
PMID: 39917766
PMC: 11798607.
DOI: 10.1093/nop/npae082.
Discovery of paradoxical genes: reevaluating the prognostic impact of overexpressed genes in cancer.
Liu D, Liu L, Che X, Wu G
Front Cell Dev Biol. 2025; 13:1525345.
PMID: 39911323
PMC: 11794808.
DOI: 10.3389/fcell.2025.1525345.
Multi-view multi-level contrastive graph convolutional network for cancer subtyping on multi-omics data.
Yang B, Cui C, Wang M, Ji H, Gao F
Brief Bioinform. 2025; 26(1).
PMID: 39899598
PMC: 11789786.
DOI: 10.1093/bib/bbaf043.
Immunocompetent murine glioblastoma stem-like cell models exhibiting distinct phenotypes.
Kardani K, Ghouse S, Din Abdul Jabbar M, Rajasubramanian N, Sanchez Gil J, Stemmer-Rachamimov A
Neurooncol Adv. 2025; 7(1):vdae215.
PMID: 39896074
PMC: 11783566.
DOI: 10.1093/noajnl/vdae215.
LDH Isoenzyme and GAA-BSA Nanoparticles: A Novel Therapy Approach for Proneural Subtype Glioblastoma Multiforme.
Yang M, Han X, Li H, Du F, Feng C, Gong A
J Cancer. 2025; 16(4):1101-1117.
PMID: 39895794
PMC: 11786042.
DOI: 10.7150/jca.98452.
Network analyses of brain tumor multiomic data reveal pharmacological opportunities to alter cell state transitions.
Bumbaca B, Huggins J, Birtwistle M, Gallo J
NPJ Syst Biol Appl. 2025; 11(1):14.
PMID: 39893170
PMC: 11787326.
DOI: 10.1038/s41540-025-00493-2.